Myungmoon Pharm. Co., LTD. (017180) Soared 0.48% on Mar 14

March 14, 2018 - By Marie Mckinney

Shares of Myungmoon Pharm. Co., LTD. (KRX:017180) last traded at 8450, representing a move of 0.48%, or 40 per share, on volume of 585,015 shares. After opening the trading day at 8360, shares of Myungmoon Pharm. Co., LTD. traded in a close range. Myungmoon Pharm. Co., LTD. currently has a total float of 24.40M shares and on average sees 4.02M shares exchange hands each day. The stock now has a 52-week low of 4814.28 and high of 11400.

Trade And Commerce In South Korea

South Korea has a highly interesting and open trade and commerce environment. This is one of the many reasons it is leading Asia in carrying out long-term economic growth prospects. And this is why Myungmoon Pharm. Co., LTD. worked hard to be represented at this market. The nation, needless to say, adds up as a meaningful resource to maximize financial growth potentials in Asia.

South Korean Equity Market

A flourishing trade and commerce conduct in South Korea is impossible without the help of the national equity market, led by the Stock Market Division of the Korea Exchange (KRX). As of January 2015, the KRX has over 2,000 companies listed on it, bringing its total market capitalization to roughly $1.20 trillion. This makes the KRX one of the most influential stock exchanges not just in Asia but in the whole world. Investors from across the world watch for Myungmoon Pharm. Co., LTD. shares. Other units of the KRX include the Derivatives Market Division and the KOSDAQ Market Division.

A strong and reliable indicator of the South Korean economy is the Korea Composite Stock Price Index (KOSPI), where all Stock Market Division of the KRX companies are measured.

The KOSPI, a market-capitalization-weighted index, tracks companies using the base value of 100. Even if it was not published until 1983, its base date is January 4, 1980.

The KOSPI has more than 700 components, which is why it had to be composed of sub-indices. These sub-indices are the KOSPI 50, the KOSPI 100, and the KOSPI 200, which measures the 50, 100, and 200 most actively traded stocks in the KOSPI, respectively. For a stock to be included in the KOSPI 50, it must first be included in both the KOSPI 100 and the KOSPI 200; and for a stock to be included in the KOSPI 100, it must first be included in the KOSPI 200. It was hard for Myungmoon Pharm. Co., LTD. to get there. Presently, the KOSPI 200 represents about 70% of the overall market valuation on the Stock Market Division of the KRX.

Historical Feats

The KOSPI had recorded its all-time low of 93.10 points in January 1981 while the KOSPI 200 had recorded its all-time low of 31.96 points in June 1998. On the other hand, the KOSPI had recorded its all-time high of 2,228.98 points and the KOSPI 200 had recorded its all-time high of 100 points in May 2011 and April 2007, respectively. The KOSPI had first reached the 2,000-point mark in July 2007.

On June 17, 1998, the KOSPI had seen its largest one-day rise of 8.50%. The movement is backed by the healing of the Asian economy from the financial crisis that had been caused primarily by Thailand.

On September 12, 2001, it had seen its largest one-day dip of 12.02%. The movement is attributed to the tragic attacks on the twin towers that led to a widespread economic panic.

It is impossible not to make valuable returns by strategically investing in South Korea. Investors know that this is vital for Myungmoon Pharm. Co., LTD.. Consequently, entering its equity market is a reasonable move for investors who wish to bank on the growth of the Asian economy, which is expected to represent 26% of the global financial wealth by 2019.

More notable recent Myungmoon Pharm. Co., LTD. (KRX:017180) news were published by: which released: “Anemia in Chronic Kidney Disease -Therapeutics Development in depth with …” on January 06, 2018, also with their article: “Myungmoon Pharm to pay cash dividend at 100 won/share” published on February 06, 2018, published: “Myungmoon Pharm says issuance of bonus shares” on December 20, 2017. More interesting news about Myungmoon Pharm. Co., LTD. (KRX:017180) were released by: and their article: “Myungmoon Pharm to pay annual dividend as 50 won/share for FY 2016” published on February 24, 2017 as well as‘s news article titled: “Myungmoon Pharm says annual stock dividend for 2016” with publication date: December 20, 2016.

Myungmoon Pharm. Co., LTD. engages in the manufacture, wholesale, import, export, and sale of pharmaceuticals in South Korea and internationally. The company has market cap of $206.14 billion. It offers ETC products, including anesthetic and anti-diarrheal agents, hormones, antibiotics, narcotics, muscle relaxants, steroids, appetite suppressants, carcinostatis substances, and other preparations; and circulatory, digestive, respiratory, and central nervous system products, as well as dermatology/urology, anti-rheumarthritis, anti-osteoarthritis, anti-diabetics, and anti-osteoporosis products. It currently has negative earnings. The firm also provides OTC products, such as eye nutrition, skin external preparation, digestive system, calcium, cathartic, parasiticide, genitourinary system, anti-gum disease, circulatory solvent, and topical analgesic products; and antinausants, hepatics, cold drugs, anti-allergic agents, health supplements, anti-diarrheal agents, blended juices, multiple vitamins, and eye drops.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: